www.bioprocessintl.com Open in urlscan Pro
172.64.144.102  Public Scan

Form analysis
0 forms found in the DOM

Text Content

BioProcess International is part of the Informa Connect Division of Informa PLC
Informa PLC|ABOUT US|INVESTOR RELATIONS|TALENT
This site is operated by a business or businesses owned by Informa PLC and all
copyright resides with them. Informa PLC's registered office is 5 Howick Place,
London SW1P 1WG. Registered in England and Wales. Number 8860726.

BPI EventsAboutSubscribeContribute

Subscribe

Subscribe
REGISTERSign in

Upstream

RELATED TOPICS

 * Bioreactors
 * Expression Platforms
 * Biochemicals/Raw Materials

 * Cell Culture Media
 * Microbial Cell Culture
 * Perfusion Cell Culture

RECENT IN UPSTREAM

See all
turbulent flow image
Bioreactors
Lessons in Bioreactor Scale-Up, Part 2: A Refresher on Fluid Flow and
MixingLessons in Bioreactor Scale-Up, Part 2: A Refresher on Fluid Flow and
Mixing
byMuhammad Arshad Chaudhry
Jun 12, 2024
Downstream

RELATED TOPICS

 * Filtration
 * Viral Clearance

 * Separation/Purification
 * Chromatography

RECENT IN DOWNSTREAM

See all
Thermo Fisher/AstraZeneca webinar title slide
Chromatography
Manufacturing Friendly Aggregate Clearance in Downstream Processing of
Bispecific and Traditional Antibodies Using a Novel POROs Mixed-Mode
Chromatography MediaManufacturing Friendly Aggregate Clearance in Downstream
Processing of Bispecific and Traditional Antibodies Using a Novel POROs
Mixed-Mode Chromatography Media
byBPI Contributor
Jun 6, 2024
30 Min View
Manufacturing

RELATED TOPICS

 * Biosimilars
 * Continuous Bioprocessing
 * Facility Design/Engineering
 * Formulation

 * Single Use
 * Fill/Finish
 * Information Technology

RECENT IN MANUFACTURING

See all
thumbnail
Upstream & Downstream Processing
Sustainability takes center stage on last day of ESACT 2024Sustainability takes
center stage on last day of ESACT 2024
byJosh Abbott
Jul 17, 2024
2 Min Read
eBook cover
Fill/Finish
eBook: Drug Delivery — New Formats for Novel BiopharmaceuticalseBook: Drug
Delivery — New Formats for Novel Biopharmaceuticals
byCheryl Scott, Vincenza Pirontiand 2 more
Jun 26, 2024
Analytical

RELATED TOPICS

 * QA/QC
 * Cell Line Development
 * PAT
 * Product Characterization

 * Bioanalytical Methods
 * Process Development
 * Assays

RECENT IN ANALYTICAL

See all
hand cleaning equipment
QA/QC
Extending the Visible Residue Limit Approach to Potent Therapeutic Proteins —
Part 2: Test Results and ConclusionsExtending the Visible Residue Limit Approach
to Potent Therapeutic Proteins — Part 2: Test Results and Conclusions
byRam Kouda, Syeda Tabassumand 3 more
Jun 12, 2024
scientists looking through microscope
QA/QC
Establishing a Life Cycle for Relaundered Cleanroom GarmentsEstablishing a Life
Cycle for Relaundered Cleanroom Garments
byTim Sandle
Jun 12, 2024
Business

RELATED TOPICS

 * Bioregions
 * Careers & Training
 * Contract Services
 * Economics

 * Pre-Clinical & Clinical Trials
 * Risk Management
 * Intellectual Property
 * Regulatory Affairs

RECENT IN BUSINESS

See all
Resilience logo
Sponsored Content
Built to Serve Innovation: A Briefing on Commercial Readiness at ResilienceBuilt
to Serve Innovation: A Briefing on Commercial Readiness at Resilience
byBPI Contributor
Jun 25, 2024
15 Min View
scientist at computer
Bioregions
US–India Collaborative Innovations for Rapid Drug DiscoveryUS–India
Collaborative Innovations for Rapid Drug Discovery
byJitendra Kumar
Jun 12, 2024
Therapeutic Modalities

RELATED TOPICS

 * Cell Therapies
 * Gene Therapies
 * MAb
 * Emerging Therapeutics

 * Personalized Medicine
 * Large Molecule Development
 * Vaccines

RECENT IN THERAPEUTIC MODALITIES

See all
iStock photo
Cell Therapies
Analytical Considerations for Gene-Modified Hematopoietic Stem and Progenitor
Cell Therapies: Part 2 — Starting Materials and Drug SubstancesAnalytical
Considerations for Gene-Modified Hematopoietic Stem and Progenitor Cell
Therapies: Part 2 — Starting Materials and Drug Substances
byBrent Morse, Alicja Fiedorowicz
Jun 19, 2024
handshake
Cell Therapies
Elevating the CGT Manufacturing Game: How Outsourcing Enables SuccessElevating
the CGT Manufacturing Game: How Outsourcing Enables Success
byOmkar Kawalekar, Audrey Greenbergand 1 more
Jun 12, 2024
BioProcess Insider

RELATED TOPICS

 * Deal-Making
 * Facilities & Capacity
 * Global Markets
 * Regulations

 * Therapeutic Class
 * Upstream & Downstream Processing
 * Webcasts
 * BioProcess Insider Podcasts

RECENT IN BIOPROCESS INSIDER

See all
thumbnail
Bioprocess Insider
AI is stronger and faster. But is it better?AI is stronger and faster. But is it
better?
byJosh Abbott
Jul 17, 2024
2 Min Read
thumbnail
Upstream & Downstream Processing
Sustainability takes center stage on last day of ESACT 2024Sustainability takes
center stage on last day of ESACT 2024
byJosh Abbott
Jul 17, 2024
2 Min Read


 * Global Markets
 * Bioprocess Insider




BEYOND HUMIRA: ABBVIE LOOKS TO $35BN PIPELINE FOR FUTURE GROWTHBEYOND HUMIRA:
ABBVIE LOOKS TO $35BN PIPELINE FOR FUTURE GROWTH

Dan Stanton, Managing editor

January 10, 2019

3 Min Read
A screenshot from a US televeision advertisement for Humira, the world's top
selling drug by revenue


With the world’s best-selling drug now facing direct biosimilar competition,
AbbVie says it is confident its robust pipeline will deliver double-digit growth
going forward.

In 2018, the first biosimilar versions of Humira (adalimumab) were launched in
Europe and other non-US markets. Meanwhile in October, Sandoz became the third
firm to receive US Food and Drug Administration (FDA) approval for a Humira
biosimilar. It is, therefore, fair to say sales of the world’s top selling drug
– Humira clocked in sales of $18.4 billion in 2017, and $15 billion for the
first nine months of 2018 – are under threat.



But speaking at the 37th JP Morgan Healthcare Conference in San Francisco, Mike
Severino, AbbVie’s vice chairman and president, said new product launches will
offset any losses from biosimilar competition. “We expect revenue from our
non-Humira growth platform, including our durable base business and innovative
new products, will grow to more than $35 billion in 2025.”



A screenshot from a US televeision advertisement for Humira, the world’s top
selling drug by revenue



He added direct biosimilar competition will have an impact of more than $6
billion in international Humira business, but AbbVie has “long been diligently
planning for this event,” and is fully prepared.

“We are now facing direct biosimilar competition across the majority of
international markets. And as I just outlined, we expect to drive strong growth
despite its impact in 2019.” Numerous settlement agreements made over the past
12 months mean the firm does not anticipate direct biosimilar competition in the
US until 2023.




NEW PRODUCT LAUNCHES

In fact the firm is aiming for double-digit growth in 2019 and beyond, driven by
“significant investment” to support new product launches.

“As we enter this important time for our company, you will see the next stage of
our strategy play out. We have built a tremendous growth platform in
hematology/oncology with Imbruvica [ibrutinib] and Venclexta [venetoclax
tablets], the leading mechanisms in this area. Combined, they will drive
significant growth during this biosimilar period.”



For the nine months up to October 2018, Imbruvica pulled in global revenues of
$1.9 billion. Venclexta is a first-in-class medicine that selectively binds and
inhibits the B-cell lymphoma-2 (BCL-2) protein co-developed and commercialized
by AbbVie and Roche. For the first nine months 2018, the drug pulled in $220
million.

While Severino said these will grow, he also highlighted two immunology assets,
upadacitinib and risankizumab, which “have the potential to provide improved
outcomes for patients across a number of indications and ultimately replace
Humira as the leading immunology assets.”

The firm submitted a Biologics License Application (BLA) for risankizumab for
moderate to severe plaque psoriasis in April 2018. In October, AbbVie said Phase
III trials for upadacitinib in ulcerative colitis had been initiated.

Correction: The original article placed Humira sales for the first nine months
of 2018 as $13.5 billion, rather than $15 billion, as reported by AbbVie.




ABOUT THE AUTHOR(S)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and
processing industries.


Founder and editor of Bioprocess Insider, a daily news offshoot of publication
Bioprocess International, with expertise in the pharmaceutical and healthcare
sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech,
bioprocessing methods and equipment, drug delivery, regulatory affairs and
business development.


From London, UK originally but currently based in Montpellier, France through a
round-a-bout adventure that has seen me live and work in Leeds (UK), London, New
Zealand, and China.

See more from Dan Stanton

You May Also Like

--------------------------------------------------------------------------------

Global Markets

China GLP-1s: Novo Nordisk invests $556m, Aurisco expands
08/04/2024
Global Markets

Gene therapy firm Locanabio to close by end of 2023
07/11/2023
Global Markets

CPHI report: China develops own biologics niche; no longer low-cost manufacturer
25/09/2023
Global Markets

Sustainability: Biomanufacturing challenges and potential solutions
07/08/2023



WEBINARS

ask the expert webcast
ATE Webcasts
More Product Faster: Maximize mAbs, Cell Therapy, and Gene Therapy Production
with Upstream Process IntensificationMore Product Faster: Maximize mAbs, Cell
Therapy, and Gene Therapy Production with Upstream Process Intensification

scientist at OPUS 80R
Sponsored Content
Reduce Risk and Enable Continuous Manufacturing Using Pre-Packed Columns for
Multicolumn ChromatographyReduce Risk and Enable Continuous Manufacturing Using
Pre-Packed Columns for Multicolumn Chromatography
Resilience logo
Sponsored Content
Built to Serve Innovation: A Briefing on Commercial Readiness at ResilienceBuilt
to Serve Innovation: A Briefing on Commercial Readiness at Resilience

Latest Content

 * AI is stronger and faster. But is it better?
   
   July 17, 2024
   |
   2 Min Read

 * Sustainability takes center stage on last day of ESACT 2024
   
   July 17, 2024
   |
   2 Min Read

 * Legend Bio said to have received takeover bid; Stock price climbs
   
   July 16, 2024
   |
   2 Min Read

 * A Comprehensive and Flexible Approach to CMC for Fab and Fc-Fusion
   Development Programs
   
   July 15, 2024
   |
   1 Min Read

Sep 23 - Sep 26, 2024
Sep 23 - Sep 26, 2024
Learn from the brightest minds in bioprocessing! The BPI US 2024 scientific
agenda includes 200+ of the industry's top scientists to present the latest
updates on how to improve efficiencies across all phases of biopharmaceutical
development and production.
Learn More
BPI Podcasts

CONTENT SPOTLIGHT


PODCAST: MILLIPORESIGMA SAYS EDUCATION VITAL TO CREATING UNBREAKABLE CHAIN FOR
SUSTAINABILITY

MilliporeSigma discusses the importance of people, education, and the benefits
of embracing discomfort to bolster sustainability efforts.

Listen Now





BPI CONTENT

BPI ArchiveBioProcess Insider NewsSubscribe to BioProcess Insider Newsletter

RESOURCES

EventsWebinarsWhite PapersPostersVideosPodcasts

ABOUT BPI

Who We AreEditorial AdvisorsAuthor GuidelinesAdvertising/Media KitList
Rental/ReprintsCareers

JOIN US

Subscribe
Subscribe

FOLLOW US



Copyright © 2024 Informa Connect Limited. Registered in England & Wales with
number 01835199, registered office 5 Howick Place, London, SW1P 1WG.

Cookie Policy|Privacy|Terms|CCPA: Do not sell my personal info

Cookies Button


ABOUT COOKIES ON THIS SITE

We and our partners use cookies to enhance your website experience, learn how
our site is used, offer personalised features, measure the effectiveness of our
services, and tailor content and ads to your interests while you navigate on the
web or interact with us across devices. By clicking "Continue" or continuing to
browse our site you are agreeing to our and our partners use of cookies. For
more information seePrivacy Policy
CONTINUE




COOKIE POLICY

When you visit any website, it may store or retrieve information on your
browser, mostly in the form of cookies. This information might be about you,
your preferences or your device and is mostly used to make the site work as you
expect it to. The information does not usually directly identify you, but it can
give you a more personalized web experience. Because we respect your right to
privacy, you can choose not to allow some types of cookies. Click on the
different category headings to find out more and change our default settings.
However, blocking some types of cookies may impact your experience of the site
and the services we are able to offer.
More information
Allow All


MANAGE CONSENT PREFERENCES

STRICTLY NECESSARY COOKIES

Always Active

These cookies are necessary for the website to function and cannot be switched
off in our systems. They are usually only set in response to actions made by you
which amount to a request for services, such as setting your privacy
preferences, logging in or filling in forms.    You can set your browser to
block or alert you about these cookies, but some parts of the site will not then
work. These cookies do not store any personally identifiable information.

PERFORMANCE COOKIES

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They help us to know which pages are the
most and least popular and see how visitors move around the site.    All
information these cookies collect is aggregated and therefore anonymous. If you
do not allow these cookies we will not know when you have visited our site, and
will not be able to monitor its performance.

FUNCTIONAL COOKIES

Functional Cookies

These cookies enable the website to provide enhanced functionality and
personalisation. They may be set by us or by third party providers whose
services we have added to our pages.    If you do not allow these cookies then
some or all of these services may not function properly.

TARGETING COOKIES

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may
be used by those companies to build a profile of your interests and show you
relevant adverts on other sites.    They do not store directly personal
information, but are based on uniquely identifying your browser and internet
device. If you do not allow these cookies, you will experience less targeted
advertising.

Back Button


COOKIE LIST



Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

Confirm My Choices